202 related articles for article (PubMed ID: 34791156)
1. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
[TBL] [Abstract][Full Text] [Related]
2. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.
Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q
Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565
[TBL] [Abstract][Full Text] [Related]
3. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
[TBL] [Abstract][Full Text] [Related]
4. Oncological characteristics of epidermal growth factor receptor-mutated clinical stage IA lung adenocarcinoma with radiologically pure-solid appearance.
Hattori A; Matsunaga T; Fukui M; Tomita H; Takamochi K; Suzuki K
J Thorac Cardiovasc Surg; 2023 Nov; ():. PubMed ID: 37995863
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
6. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
Lee KH; Chung JH; Cho S; Lee JS; Kim H
Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
8. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
Xu Y; Zheng M; Wang N; Wang R
Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
[TBL] [Abstract][Full Text] [Related]
10. Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.
Aokage K; Miyoshi T; Wakabayashi M; Ikeno T; Suzuki J; Tane K; Samejima J; Tsuboi M
Lung Cancer; 2021 Oct; 160():8-16. PubMed ID: 34365179
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
12. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
[TBL] [Abstract][Full Text] [Related]
13. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
[TBL] [Abstract][Full Text] [Related]
14. Impact of a Ground-glass Opacity Component on c-Stage IA Lung Adenocarcinoma.
Li M; Xi J; Sui Q; Kuroda H; Hamanaka K; Bongiolatti S; Hong G; Zhan C; Feng M; Wang Q; Tan L
Semin Thorac Cardiovasc Surg; 2023 Winter; 35(4):783-795. PubMed ID: 35907612
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis.
Matsumura Y; Owada Y; Yamaura T; Muto S; Osugi J; Hoshino M; Higuchi M; Ohira T; Suzuki H; Gotoh M
Interact Cardiovasc Thorac Surg; 2016 Aug; 23(2):216-22. PubMed ID: 27173985
[TBL] [Abstract][Full Text] [Related]
16. Air bronchogram on chest CT in radiological pure-solid appearance lung cancer: Correlation analysis with genetic pathological features and survival outcomes.
Wang Z; Zhu W; Yang M; Du H; Zhou F; Song N; Wan Z; Zhu J; Li W
Eur J Radiol; 2023 Dec; 169():111194. PubMed ID: 37976762
[TBL] [Abstract][Full Text] [Related]
17. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.
Hong SJ; Kim TJ; Choi YW; Park JS; Chung JH; Lee KW
Eur Radiol; 2016 Oct; 26(10):3660-8. PubMed ID: 26787602
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
Lee JS; Kim EK; Kim KA; Shim HS
Cancer Res Treat; 2024 Jan; 56(1):104-114. PubMed ID: 37499696
[TBL] [Abstract][Full Text] [Related]
19. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
20. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]